Personalised and 3D-printed medical devices: three distinctions Australian suppliers need to make

1. Patient-matched is different from custom-made

A patient-matched medical device is designed by its manufacturer within a specified design envelope to match an individual’s anatomical, physiological or pathological features. Its production processes are capable of being validated or verified and reproduced. This can include routinely produced devices whose dimensions vary for each patient.

A custom-made device is more narrowly framed. It is made for the sole use of a particular patient or health professional in accordance with a written request that specifies particular design characteristics. The category is intended for circumstances where no suitable device in the ARTG is available for the individual’s needs. A health professional’s written request alone does not make every personalised device custom-made.

2. Adaptation is different from manufacture

An adaptable medical device is mass-produced and then assembled or adapted for an individual according to the manufacturer’s validated instructions. The person performing the adaptation needs to remain within those instructions. Moving outside the validated configuration may change who is treated as the manufacturer and which obligations apply.

Healthcare facilities should therefore document whether they are selecting options provided by the original manufacturer, modifying a finished device, or creating a new device. The practical steps may look similar, but the regulatory consequences can be very different.

3. 3D printing does not determine the category

Additive manufacturing can be used for patient-matched, custom-made or other medical devices. Classification depends on intended purpose, design responsibility, risk rules and the production model—not the fact that a printer was used.

A sound regulatory file should connect the clinical input, design envelope, software workflow, material controls, production validation, final release and post-market information. When several organisations contribute to the workflow, their responsibilities should be explicit.

Preparing for the 2029 transition point

The TGA states that the transition period for patient-matched medical devices ends on 1 July 2029. After that date, patient-matched devices—including notified devices—must generally be included in the ARTG before import, supply or export unless another exemption, exclusion or approval applies.

• Catalogue current personalised-device families and intended purposes.
• Identify who controls the design and who is the legal manufacturer.
• Document the design envelope and repeatability of the production process.
• Reassess classification and conformity-assessment evidence.
• Plan sponsor, evidence and ARTG inclusion activities well before July 2029.